Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1001-1008

  Mueller, E A ^a   Kovarik, J M ^a   Uresin Y ^a   Preisig Fluckiger S S ^b   Hensel, S ^c   Lucker P W ^b   Holt, B ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Institute for Clinical Pharmacology   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN D; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; UNCLASSIFIED DRUG; VALSPODAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG EXPOSURE; DRUG FORMULATION; FAT INTAKE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROEMULSION; MULTIDRUG RESISTANCE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030782687     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04280.x     Document Type: Article

References (21)

1. Sikic BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993:11:1629-1635.
2. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. Cancer 1993;72:3484-3488.
3. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, et al: Clinical trials of modulation of multidrug resistance. Cancer 1993; 72:3502-3514.
4. Gavériaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F: SDZ-PSC-833, a nonimmunosuppressivo cyclosporine analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-234.
5. Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSG 833. Cancer Res 1991:51:4226-4233.
6. G. Boote DJ, Dennis IF, Twentymann PR, Osbourne RJ, Laburte C, Hensel S, et al: A phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance. J Clin Oncol 1996; 14: 610-618.
7. Sonneveld P, Marie J-P, Huisman C, Vekhoff A, Shoester M, Faussât AM, et al: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexametha-sone) in refractory multiple myeloma. A phase I study. Leukemia 1996:10:1741-1750.
8. Kovarik JM, Mueller EA, Richard F, Tetzloff W: Optimizing tho absorption of valspodar, a P-glycoprotein modulator. II: quantifiying its pharmacokinetic variability and refining the bioavailability estimate. XXX.
9. Schuirmann DJ: A comparison of the two one-sided procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
10. Nelson LS: Testing two correlated variances. Technometrics 1965:7:447-449.
11. Chow SC, Liu JP: Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, Inc., 1992:349-356.
12. Twentymann PR:. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992:43:109-117.
13. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-495.
14. Kovarik JM, Mueller EA, Kallay Z, Smith HT, Lison AE, Arns W, Renner E: Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation. J Clin Pharmacol 1995;35:1136-1143.
15. Kovarik JM, Mueller EA, Niese D: Clinical development of a cyclosporine microomulsion in transplantation. Ther Drug Monit 1996;18:429-434.
16. Mueller EA, Kovarik JM, van Breo JB, Totzloff W, Grevol J, Kutz K: Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994:11:301-304.
17. Kovarik JM, Mueller EA, van Bree JB, Flückiger SS, Lange H, Schmidt B, et al: Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994:58:658-663.
18. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lücker P\V, Kutz K: Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994;11:151-155.
19. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, et al: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992:10:1624-1634.
20. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, et al: Phase I trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-1660.
21. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987:84:7735-7738.